scholarly journals Intensive Blood Pressure Treatment Does Not Improve Cardiovascular Outcomes in Centrally Obese Hypertensive Individuals With Diabetes: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial

Diabetes Care ◽  
2012 ◽  
Vol 35 (7) ◽  
pp. 1401-1405 ◽  
Author(s):  
J. I. Barzilay ◽  
A. G. Howard ◽  
G. W. Evans ◽  
J. L. Fleg ◽  
R. M. Cohen ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Risk ◽  
Cardiovascular Outcomes ◽  
Pressure Treatment ◽  
Blood Pressure Treatment ◽  
Intensive Blood Pressure

Intensive Blood Pressure Treatment in Adults Aged 60 Years or Older

2017 ◽  
Vol 167 (4) ◽  
pp. 288
Author(s):  
Gulistan Bahat ◽  
Birkan Ilhan ◽  
Asli Tufan ◽  
Mehmet Akif Karan
Keyword(s):  
Blood Pressure ◽  
Pressure Treatment ◽  
Blood Pressure Treatment ◽  
Intensive Blood Pressure

scholarly journals Risk–benefit profile of intensive blood pressure treatment

2018 ◽  
Vol 6 (8) ◽  
pp. 601-602 ◽  
Author(s):  
João Sérgio Neves ◽  
Lia Leitão ◽  
Rita Magriço ◽  
Catarina Viegas Dias ◽  
Miguel Bigotte Vieira
Keyword(s):  
Blood Pressure ◽  
Pressure Treatment ◽  
Blood Pressure Treatment ◽  
Intensive Blood Pressure

scholarly journals Impact of cumulative SBP and serious adverse events on efficacy of intensive blood pressure treatment

2019 ◽  
Vol 37 (5) ◽  
pp. 1058-1069 ◽  
Author(s):  
Oscar L. Rueda-Ochoa ◽  
Lyda Z. Rojas ◽  
Shahzad Ahmad ◽  
Cornelia M. van Duijn ◽  
Mohammad A. Ikram ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Adverse Events ◽  
Pressure Treatment ◽  
Serious Adverse Events ◽  
Blood Pressure Treatment ◽  
Intensive Blood Pressure

scholarly journals 2017 ACC/AHA Blood Pressure Treatment Guideline Recommendations and Cardiovascular Risk

2018 ◽  
Vol 72 (11) ◽  
pp. 1187-1197 ◽  
Author(s):  
Lisandro D. Colantonio ◽  
John N. Booth ◽  
Adam P. Bress ◽  
Paul K. Whelton ◽  
Daichi Shimbo ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Risk ◽  
Treatment Guideline ◽  
Pressure Treatment ◽  
Blood Pressure Treatment

Benefits and Harms of Intensive Blood Pressure Treatment in Adults Aged 60 Years or Older

2017 ◽  
Vol 166 (6) ◽  
pp. 419 ◽  
Author(s):  
Jessica Weiss ◽  
Michele Freeman ◽  
Allison Low ◽  
Rochelle Fu ◽  
Amy Kerfoot ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Pressure Treatment ◽  
Blood Pressure Treatment ◽  
Intensive Blood Pressure

P796Intensive blood pressure treatment significantly increases visit-to-visit systolic blood pressure variability. A randomized clinical trial

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
O L Rueda-Ochoa ◽  
L Z Rojas Sanchez ◽  
M A Ikram ◽  
J W Deckers ◽  
O H Franco ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Primary Outcome ◽  
Total Population ◽  
Standard Treatment ◽  
Intensive Treatment ◽  
Pressure Treatment ◽  
Treatment Groups ◽  
Blood Pressure Treatment ◽  
Intensive Blood Pressure

Abstract Background Intensive blood pressure lowering is increasingly gaining attention. Besides higher baseline blood pressure, visit-to-visit variability has showed association with target organ damage and major adverse cardiovascular outcomes in multiple medical reports. Purpose Our aim was to assess the effect of intensive treatment on systolic blood pressure (SBP) visit-to-visit variability in the SPRINT trial population during follow-up. Methods We included 9068 SPRINT participants with 128139 repeated SBP measurements. Participants were randomly assigned to intensive (SBP <120 mmHg) vs standard treatment (SBP between 135–139 mmHg). The primary outcome was a composite outcome of myocardial infarction, other acute coronary syndromes, acute decompensated heart failure, stroke, and cardiovascular mortality. We calculated the coefficient of variation (CV) and standard deviation (SD), taking into account all SBP measurements prior to the SPRINT primary outcome. Comparison of CV between intensive and standard treatment in the total SPRINT population and among different subgroups was made. Results CVs in intensive treatment groups were higher in total population and in all groups under study (See table). While second and third CV quartile showed a larger tendency to increase the risk for the primary SPRINT outcome in the intensive treatment compared to the standard treatment group, fourth CV quartiles were significantly associated with increase in primary SPRINT outcome in both intensive and standard treatment groups. Coefficient of variation in SPRINT trial Group Intensive treatment Standard treatment Total population 9.80 (3.22)* 8.52 (2.96) Females 10.46 (3.29)* 9.18 (3.15) Black person 9.99 (3.38)* 8.82 (3.15) Prevalence CKD 10.14 (3.22)* 9.12 (3.06) Prevalence CVD 10.28 (3.32)* 8.93 (3.23) ≥75 year 10.40 (3.18)* 9.01 (3.07) SAEs 10.30 (3.39)* 9.08 (3.13) (CKD: chronic kidney disease; CVD: cardiovascular disease; SAEs: serious adverse events. *P<0.05). Conclusions Intensive blood pressure treatment significantly increases SBP visit-to-visit variability in total SPRINT population and in all subgroups under study. Additional longitudinal studies with long-term follow-up are warranted to evaluate the impact of increases in SBP visit-to-visit variability due to intensive treatment on risk of major cardiovascular events.

Sign in / Sign up

Export Citation Format

Share Document